Eli Lilly announces Verzenio survival benefit

Breast Cancer Ireland applauds this new breakthrough as Eli Lilly and Company has announced that its CDK4 & 6 inhibitor Verzenio (abemaciclib) has been found to significantly extend life in women with HR+, HER2- advanced breast cancer. To read more about this, click the link below:


Share This Article